Informatie:
Fout:
ID
34325
Beschrijving
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01754974
Link
https://clinicaltrials.gov/show/NCT01754974
Trefwoorden
Versies (1)
- 16-01-19 16-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
16 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Hepatitis C Virus (HCV) NCT01754974
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C Virus (HCV) NCT01754974
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
chronic hepatitis c, genotype 1
boolean
ID.2
Item
hcv rna ≥100,000 iu/ml at screening
boolean
ID.3
Item
liver biopsy documenting no cirrhosis (within prior 3 years). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease
boolean
ID.4
Item
naïve to prior anti-hcv therapy
boolean
ID.5
Item
infected with hcv other than genotype 1
boolean
ID.6
Item
positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv)-1/hiv-2 antibody at screening
boolean
ID.7
Item
evidence of liver disease other than hcv
boolean
ID.8
Item
active substance abuse
boolean
ID.9
Item
use of hematologic growth factors within 90 days prior to study randomization
boolean
ID.10
Item
evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria
boolean